Using Magnetic Resonance Fingerprinting to Evaluate Breast Cancer Treatment Response
Development of Magnetic Resonance Fingerprinting (MRF) to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
This study is testing a new imaging method to help doctors see how well breast cancer patients are responding to their chemotherapy before surgery, so they can make better treatment decisions and improve results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10894084 on NIH RePORTER |
What this research studies
This research focuses on developing a new imaging technique called Magnetic Resonance Fingerprinting (MRF) to assess how well breast cancer patients respond to neoadjuvant chemotherapy before surgery. The goal is to identify patients who are not responding to treatment early on, allowing for adjustments to their therapy to improve outcomes. By providing a more objective and quantitative measure of tumor changes, this approach aims to enhance the accuracy of treatment planning and reduce unnecessary side effects. The study will involve advanced imaging techniques that can detect biological changes in tumors more quickly than traditional methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with breast cancer who are scheduled to undergo neoadjuvant chemotherapy.
Not a fit: Patients who are not undergoing neoadjuvant chemotherapy or those with non-breast cancer diagnoses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment plans for breast cancer patients, improving their chances of survival.
How similar studies have performed: Previous research has shown promise in using advanced imaging techniques for monitoring treatment response, suggesting that this approach could be effective.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Chen, Yong — Case Western Reserve University
- Study coordinator: Chen, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.